Key Drivers
- Strong Liquidity
- Negative Equity
- Cash Burn
AIAI Summary
CELC is now a commercial-execution investment: REVTORPYK approval and NCCN support create meaningful upside, but the stock requires proof of payer access and prescription growth before launch burn and debt force dilutive financing. Monitor net product revenue, reimbursement uptake, and cash-runway guidance closely, as weak IV-treatment adoption would outweigh pipeline optionality.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Negative Equity
- •Cash Burn
CELC has strong near-term liquidity but faces severe risks from no revenue, persistent losses, negative free cash flow, negative equity, and reliance on debt financing.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Weak momentum
CELC remains bearish over the last month, with $80.60–$82.60 support critical and a move above $85.50 needed to signal a rebound.
Price declined from the low-to-mid $90s to $80.61
Sentiment & News
Key News Insights:
- •sNDA Submitted
- •Investor Outreach
- •Institutional Buying
Celcuity advanced REVTORPYK toward potential FDA review while expanding investor outreach and attracting institutional interest.
The developments are moderately positive for Celcuity, though FDA acceptance and approval remain key catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings